- Home
- BDTX vs MIRM Comparison
BDTX vs MIRM Comparison
Compare BDTX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- MIRM
- Stock Information
- Founded
- BDTX 2014
- MIRM 2018
- Country
- BDTX United States
- MIRM United States
- Employees
- BDTX N/A
- MIRM N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- MIRM Health Care
- Exchange
- BDTX Nasdaq
- MIRM Nasdaq
- Market Cap
- BDTX N/A
- MIRM 1.9B
- IPO Year
- BDTX 2020
- MIRM 2019
- Fundamental
- Price
- BDTX $1.61
- MIRM $40.00
- Analyst Decision
- BDTX Strong Buy
- MIRM Strong Buy
- Analyst Count
- BDTX 5
- MIRM 11
- Target Price
- BDTX $15.60
- MIRM $58.55
- AVG Volume (30 Days)
- BDTX 1.3M
- MIRM 447.2K
- Earning Date
- BDTX 05-08-2025
- MIRM 05-07-2025
- Dividend Yield
- BDTX N/A
- MIRM N/A
- EPS Growth
- BDTX N/A
- MIRM N/A
- EPS
- BDTX N/A
- MIRM N/A
- Revenue
- BDTX N/A
- MIRM $336,888,000.00
- Revenue This Year
- BDTX N/A
- MIRM $29.51
- Revenue Next Year
- BDTX N/A
- MIRM $20.27
- P/E Ratio
- BDTX N/A
- MIRM N/A
- Revenue Growth
- BDTX N/A
- MIRM 80.76
- 52 Week Low
- BDTX $1.20
- MIRM $23.14
- 52 Week High
- BDTX $7.66
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- BDTX 52.85
- MIRM 41.05
- Support Level
- BDTX $1.31
- MIRM $38.22
- Resistance Level
- BDTX $1.64
- MIRM $40.14
- Average True Range (ATR)
- BDTX 0.14
- MIRM 2.24
- MACD
- BDTX 0.04
- MIRM 0.07
- Stochastic Oscillator
- BDTX 93.26
- MIRM 48.50
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.